 Aptose Biosciences Inc NASDAQ: APTO will discontinue further clinical development of APTO-253 in hematologic malignancies and solid tumors. The decision follows the prioritization of the Companys other more advanced pipeline candidates, as well as an internal review of APTO-253, including an FDA clinical hold. 